Related references
Note: Only part of the references are listed.High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor
Damien Pouessel et al.
EUROPEAN UROLOGY (2008)
Brain metastases in patients with renal cell cancer receiving new targeted treatment
Helgi H. Helgason et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Regression of brain metastases of renal cell carcinoma with antiangiogenic therapy
Frederic Thibault et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Frank B. Furnari et al.
GENES & DEVELOPMENT (2007)
Chemoradiotherapy in malignant glioma: Standard of care and future directions
Roger Stupp et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Complete cerebral response with sunitinib for metastatic renal cell carcinoma
J. Medioni et al.
ANNALS OF ONCOLOGY (2007)
Multidisciplinary management of brain Metastases
April F. Eichler et al.
ONCOLOGIST (2007)
Chemotherapy delivery issues in central nervous system malignancy: A reality check
Leslie L. Muldoon et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Renal cell cancer presented with leptomeningeal carcinomatosis effectively treated with sorafenib
Oliver Ranze et al.
ONKOLOGIE (2007)
Renal cell carcinoma: New developments in molecular biology and potential for targeted therapies
Luciano J. Costa et al.
ONCOLOGIST (2007)
Molecularly targeted therapy in renal cell carcinoma: where do we go from here?
Brian I. Rini
EXPERT REVIEW OF ANTICANCER THERAPY (2006)
Phase II placebo-controlled randomized discontinuation trial of sorafnib in patients with metastatic renal cell carcinoma
Mark J. Ratain et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients
P Breedveld et al.
CANCER RESEARCH (2005)
Pathobiology of brain metastases
N Nathoo et al.
JOURNAL OF CLINICAL PATHOLOGY (2005)
Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice
LS Kim et al.
CLINICAL & EXPERIMENTAL METASTASIS (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Cytokine-based therapy for metastatic renal cell cancer
BJ Gitlitz et al.
UROLOGIC CLINICS OF NORTH AMERICA (2003)
Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease
NK Janzen et al.
UROLOGIC CLINICS OF NORTH AMERICA (2003)
Share Paper
